Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are general labeling-accurate (active ingredient/VMAT2 mechanism; some common adverse reactions; indication claims). However, the provided FDA label excerpts focus specifically on depression/suicidality in Huntington’s disease; several other claims (e.g., Tourette syndrome approval timing and treatment mechanism details) are not supported by the supplied label text and thus score only as partially aligned.
Category Scores
Accurate Statements
“Austedo XR and AUSTEDO may increase the risk of suicidality in patients with Huntington’s disease.”
Label Section 5.1: “AUSTEDO XR and AUSTEDO may increase the risk for suicidality in patients with Huntington’s disease.”
“Suicidal ideation was reported by 2% of patients treated with AUSTEDO, compared to no patients on placebo; no suicide attempts and no completed suicides were reported. Depression was reported by 4% of patients treated with AUSTEDO.”
Label Section 5.1 (trial data).
“Austedo XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression.”
Label Section 4 contraindications.
“All patients treated with AUSTEDO XR or AUSTEDO should be observed for new or worsening depression or suicidality; if depression or suicidality does not resolve, consider discontinuing treatment.”
Label Section 5.1.
“Patients, their caregivers, and families should be informed of the risks of depression, worsening depression, and suicidality… and instructed to report behaviors of concern promptly… Patients… who express suicidal ideation should be evaluated immediately.”
Label Section 5.1 and/or Section 17 counseling.
“The most common adverse reactions occurring in greater than 8% of AUSTEDO-treated patients were somnolence, diarrhea, dry mouth, and fatigue.”
Label Section 6.1.
“Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.”
Label Section 6.1.
Unsupported Statements
“Austedo XR received FDA approval for Tourette syndrome in September 2022.”
Not supported by the supplied label excerpts (only Sections 4, 5, 6.1, and 17 were provided).
“Austedo XR is approved for chorea associated with Huntington's disease.”
Indication not present in the supplied label excerpts.
“Austedo XR is indicated for the treatment of Tourette syndrome.”
Indication not present in the supplied label excerpts.
“Austedo XR is an extended-release formulation of deutetrabenazine.”
Deutetrabenazine is supported as active ingredient, but the statement specifies “extended-release formulation of deutetrabenazine,” which is not explicitly supported by the provided excerpts.
“Austedo XR works by reducing involuntary movements associated with these conditions.”
Mechanism of action and efficacy/clinical effect for Tourette or Huntington are not provided in the supplied excerpts.
“Common side effects… include drowsiness, fatigue, insomnia, dry mouth, constipation, nausea.”
The only common adverse reactions explicitly supported in the provided excerpts are somnolence (drowsiness), diarrhea, dry mouth, and fatigue (Section 6.1). Insomnia, constipation, and nausea are not supported by the supplied text.
“Deutetrabenazine is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2).”
Not supported by the supplied label excerpts.
“Inhibiting VMAT2 reduces the transport of monoamines like dopamine into presynaptic vesicles.”
Not supported by the supplied label excerpts.
“Reducing transport of monoamines into presynaptic vesicles decreases dopamine release.”
Not supported by the supplied label excerpts.
“Decreased dopamine release decreases downstream effects in the brain.”
Not supported by the supplied label excerpts.
“Austedo XR is an extended-release formulation designed for once-daily dosing.”
Dosing frequency is not supported by the supplied label excerpts.
Contradictions
Important Omissions
For the claim focus on depression/suicidality: the AI-generated list does not include the label’s counseling/monitoring details in full (e.g., “evaluate immediately” is not repeated in the itemized list).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The specific depression/suicidality risk claim is directly supported by the provided label excerpts (Sections 4, 5.1, and 17). Other potentially patient-relevant claims (e.g., additional side effects, dosing frequency, other indications) are not supported by the supplied excerpts, but they do not directly conflict with the provided label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims in the AI-generated list are not supported by the supplied prescribing information excerpts (especially Tourette indications/approval date, dosing frequency, VMAT2 mechanism details, and additional adverse effects such as insomnia/constipation/nausea).
Suggested Improvement
Limit statements to what is contained in the provided label sections when evaluating depression/suicidality, or provide additional FDA label excerpts (e.g., Indications, Dosage and Administration, Mechanism of Action, Adverse Reactions table) to support the broader claims.